SCHEMBL14133904

SCHEMBL14133904

CCS(=O)(=O)Nc1ccc(C2=NN(C(C)=O)C(c3ccc(F)cc3)C2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 1/20 0.69
▸ KDM4E B2RXH2 6/20 0.68
▸ ALDH1A1 P00352 6/20 0.68
▸ PKM P14618 6/20 0.68
▸ GLA P06280 3/20 0.68
▸ GAA P10253 3/20 0.68
▸ NT5E P21589 1/20 0.65
▸ CA12 O43570 1/20 0.64
▸ CA1 P00915 1/20 0.64
▸ CA2 P00918 1/20 0.64
▸ CA9 Q16790 1/20 0.64
▸ EGFR P00533 2/20 0.61
▸ HPGD P15428 3/20 0.60
▸ MAPT P10636 2/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2C9 P11712 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ HTT P42858 1/20 0.60
▸ NPSR1 Q6W5P4 1/20 0.60
▸ LMNA P02545 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14133770 0.91 KDM4E (0.83) KDM4EALDH1A1PKMGLAGAA
SCHEMBL14133630 0.91 KDM4E (0.83) PTGS2KDM4EALDH1A1PKMGLA
SCHEMBL14133875 0.89 PTGS2 (0.74) PTGS2KDM4EALDH1A1PKMGLA
SCHEMBL14133779 0.89 ALDH1A1 (0.73) KDM4EALDH1A1PKMGLAGAA
SCHEMBL14058294 0.88 PTGS2 (0.77) PTGS2KDM4EALDH1A1PKMNT5E
SCHEMBL14133539 0.88 ALDH1A1 (0.75) PTGS2KDM4EALDH1A1PKMGLA
SCHEMBL14057894 0.88 PTGS2 (0.70) PTGS2KDM4EALDH1A1PKMGLA
SCHEMBL14058664 0.85 PTGS2 (0.71) PTGS2KDM4EALDH1A1PKMGLA
SCHEMBL14058665 0.85 PTGS2 (0.71) PTGS2KDM4EALDH1A1PKMGLA
SCHEMBL14133931 0.84 KMT2A (0.64) KDM4EALDH1A1PKMGLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 PTGS2 1275/4885KDM4E 376/4885ALDH1A1 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback